التفاصيل البيبلوغرافية
| العنوان: |
Efficacy of [177Lu]Lu-DOTATATE in metastatic neuroendocrine neoplasms of different locations: data from the SEPTRALU study. |
| المؤلفون: |
Mitjavila, Mercedes, Jimenez-Fonseca, Paula, Belló, Pilar, Pubul, Virginia, Percovich, Juan Carlos, Garcia-Burillo, Amparo, Hernando, Jorge, Arbizu, Javier, Rodeño, Emilia, Estorch, Montserrat, Llana, Belén, Castellón, Maribel, García-Cañamaque, Lina, Gajate, Pablo, Riesco, Maria Carmen, Miguel, Maria Begoña, Balaguer-Muñoz, David, Custodio, Ana, Cano, Juana María, Repetto, Alexandra |
| المصدر: |
European Journal of Nuclear Medicine & Molecular Imaging; Jul2023, Vol. 50 Issue 8, p2486-2500, 15p, 4 Charts, 3 Graphs |
| مصطلحات موضوعية: |
NEUROENDOCRINE tumors, SOMATOSTATIN receptors, PEPTIDE receptors, PROGRESSION-free survival, SURVIVAL rate, HOLMIUM, LUTETIUM compounds |
| مستخلص: |
Background: Peptide receptor radionuclide therapy (PRRT) is one of the most promising therapeutic strategies in neuroendocrine neoplasms (NENs). Nevertheless, its role in certain tumor sites remains unclear. This study sought to elucidate the efficacy and safety of [177Lu]Lu-DOTATATE in NENs with different locations and evaluate the effect of the tumor origin, bearing in mind other prognostic variables. Advanced NENs overexpressing somatostatin receptors (SSTRs) on functional imaging, of any grade or location, treated at 24 centers were enrolled. The protocol consisted of four cycles of 177Lu-DOTATATE 7.4 GBq iv every 8 weeks (NCT04949282). Results: The sample comprised 522 subjects with pancreatic (35%), midgut (28%), bronchopulmonary (11%), pheochromocytoma/ paraganglioma (PPGL) (6%), other gastroenteropancreatic (GEP) (11%), and other non-gastroenteropancreatic (NGEP) (9%) NENs. The best RECIST 1.1 responses were complete response, 0.7%; partial response, 33.2%; stable disease, 52.1%; and tumor progression, 14%, with activity conditioned by the tumor subtype, but with benefit in all strata. Median progression-free survival (PFS) was 31.3 months (95% CI, 25.7–not reached [NR]) in midgut, 30.6 months (14.4-NR) in PPGL, 24.3 months (18.0-NR) in other GEP, 20.5 months (11.8-NR) in other NGEP, 19.8 months (16.8–28.1) in pancreatic, and 17.6 months (14.4–33.1) in bronchopulmonary NENs. [177Lu]Lu-DOTATATE exhibited scant severe toxicity. Conclusion: This study confirms the efficacy and safety of [177Lu]Lu-DOTATATE in a wide range of SSTR-expressing NENs, regardless of location, with clinical benefit and superimposable survival outcomes between pNENs and other GEP and NGEP tumor subtypes different from midgut NENs. [ABSTRACT FROM AUTHOR] |
|
Copyright of European Journal of Nuclear Medicine & Molecular Imaging is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
